-
Mashup Score: 7Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston - 6 day(s) ago
The new center will be a hub for both Roche and Genentech, bringing together expertise in Cardiovascular, Renal, and Metabolism, as well as for data…
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2High BP may develop at different ages and paces in East & South Asian adults in the UK - 29 day(s) ago
Research Highlights: A data analysis projected that South Asian adults living in the United Kingdom may experience elevated blood pressure nine years earlier than East Asian adults on average. The largest blood pressure disparities between South Asian …
Source: newsroom.heart.orgCategories: General Medicine News, CardiologistsTweet-
coverage by @AHAScience https://t.co/SBzvuZD2je @somijemmacho @HyperAHA
-
-
Mashup Score: 64Instability of high polygenic risk classification and mitigation by integrative scoring - 29 day(s) ago
Nature Communications – Variability exists in classifying high-risk individuals across polygenic scores for complex diseases. Here the authors show that an integrative scoring approach improves…
Source: www.nature.comCategories: General Medicine News, CardiologistsTweet-
Individual polygenic risk scores for the same trait can yield different results due to various derivation differences. Our study led by A. Misra & w @AniruddhPatelMD demonstrates how successive score integration can improve accuracy & stability https://t.co/9VtRU8VtJy… https://t.co/X0dSNaGD0k https://t.co/02yKmotpOz
-
-
Mashup Score: 157
People of South Asian descent are more likely to be affected by heart disease, but their risks often go unnoticed. Researchers are looking to genetics to learn more and prevent early deaths.
Source: www.npr.orgCategories: General Medicine News, CardiologistsTweet-
So fantastic that @NPR featured the unexplained troublingly high rates of heart disease among S Asian individuals, and our research efforts @ourhealthstudy to address these issues! https://t.co/TvEZeN3nt3 https://t.co/mleqo53egY
-
-
Mashup Score: 153
People of South Asian descent are more likely to be affected by heart disease, but their risks often go unnoticed. Researchers are looking to genetics to learn more and prevent early deaths.
Source: www.npr.orgCategories: General Medicine News, CardiologistsTweet-
So fantastic that @NPR featured the unexplained troublingly high rates of heart disease among S Asian individuals, and our research efforts @ourhealthstudy to address these issues! https://t.co/TvEZeN3nt3 https://t.co/mleqo53egY
-
-
Mashup Score: 3Proact - FahedLab - 1 month(s) ago
Our team leads the NHLBI-funded PROACT trials, aimed at testing the impact of a proactive, polygenic-risk based detection strategy on cardiovascular health and coronary atherosclerosis. The PROACT trials leverage the power of polygenic risk scores in identifying people at high risk of heart attack currently “flying under the radar” and advances in noninvasive coronary plaque imaging. The innovative design uses a genomic-based enrichment strategy for a clinical trial to test single or dual targeting of lipid-lowering and inflammation in coronary atherosclerosis. PROACT 1: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health NCT05819814 The purpose of PROACT 1 is to assess the impact of disclosing a high polygenic risk score result for coronary artery disease on change in cardiovascular health. PROACT 2: Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine NCT05850091 The p
Source: fahedlab.comCategories: General Medicine News, CardiologistsTweet-
@khurramn1 @MariosGeorgakis @ESC_Journals @somijemmacho @skathire @DrMarthaGulati @RonBlankstein @MichaelJBlaha Can consider both for primary prevention! https://t.co/qRtQPVapx7 @aklfahed
-
-
Mashup Score: 14Grading the Groundhogs - 1 month(s) ago
In honor of Groundhog Day and in the spirit of fun, we pitted groundhogs from all over the United States against each other—and data from the National Centers for Environmental Information—to see who’s the most accurate.
Source: www.noaa.govCategories: General Medicine News, CardiologistsTweet-
Punxsutawney Phil is only 35% accurate(!) but Staten Island Chuck is 85% accurate https://t.co/jcNWy2Wgyc Unlike Punxsutawney Phil, Staten Island Chuck predicts *early* Spring https://t.co/6eP6P9IwgR #GroundhogDay https://t.co/pBREJbNU8z
-
-
Mashup Score: 13OPPORTUNISTIC ASSESSMENT OF CARDIOVASCULAR RISK USING AI-DERIVED STRUCTURAL AORTIC AND CARDIAC PHENOTYPES FROM NON-CONTRAST CHEST COMPUTED TOMOGRAPHY - 1 month(s) ago
Background Primary prevention of cardiovascular disease relies on accurate risk assessment using scores such as the Pooled Cohort Equations (PCE) and PREVENT. However, necessary input variables for these scores are often unavailable in the electronic health record (EHR), and information from routinely collected data (e.g., non-contrast chest CT) may further improve performance. Here, we test whether a risk prediction model based on structural features of the heart and aorta from chest CT has added value to existing clinical algorithms for predicting major adverse cardiovascular events (MACE). Methods We developed a LASSO model to predict fatal MACE over 12 years of follow-up using structural radiomics features describing cardiac chamber and aorta segmentations from 13,437 lung cancer screening chest CTs from the National Lung Screening Trial. We compared this radiomics model to the PCE and PREVENT scores in an external testing set of 4,303 individuals who had a chest CT at a Mass Gener
Source: www.medrxiv.orgCategories: General Medicine News, CardiologistsTweet-
Delighted to contribute to this preprint led by @danieloo2024 @VineetRaghu2 @CIRC_MGH using structural cardiac radiomics from non-ECG-gated chest CTs to improve CV risk prediction beyond PCE & PREVENT https://t.co/rtU1h8eOWB @medrxivpreprint https://t.co/bdgXHgn9Xm
-
-
Mashup Score: 128Dynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course | Circulation: Genomic and Precision Medicine - 2 month(s) ago
BACKGROUND: Earlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. We sought to understand how the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction. METHODS: A longitudinal study was performed using data from 2 cohort studies: the FOS (Framingham Offspring Study) with 3588 participants aged 19 to 57 years and the UKB (UK Biobank) with 327 837 participants aged 40 years to 70 years. A total of 134 765 and 3 831 734 person-time years were observed in FOS and UKB, respectively. Hazard ratios for CAD were calculated for polygenic risk score (PRS) and clinical risk factors at each age of enrollment. The relative importance of PRS and pooled cohort equations in predicting CAD events was also evaluated by age groups. RESULTS: The importance of CAD PRS diminished
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet-
Delighted to share our study by @tigerstatdoc with @aklfahed on adding in a CAD polygenic risk score to clinical factors to boost CAD risk prediction, particularly for recovering premature CAD events https://t.co/oLRpkE3cNW @Circ_Gen https://t.co/TJIVDbhKUC
-
-
Mashup Score: 33
Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant in pati…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet-
RT @SidPatelMD: 🚨The AZALEA-TIMI 71 Trial now in @NEJM from @TIMIStudyGroup https://t.co/wzIM2vL8Le 🧵 below👇🏼 https://t.co/UDzlgtjOBb
-
Roche announces launch of Roche Genentech Innovation Center Boston based at Harvard’s Enterprise Research Campus in Allston https://t.co/3hUYezPQAd @Roche @genentech https://t.co/4hB6I8QK6T